Seeking Alpha

FDA allows marketing for Affymetrix CytoScan Dx Assay

  • The FDA clears a first-of-a-kind blood test, developed by Affymetrix (AFFX -0.3%), that can help predict intellectual disabilities in infants by analyzing their genetic code.
  • The CytoScan Dx Assay test detects variations in patients' chromosomes that are linked to Down syndrome, DiGeorge syndrome and other developmental disorders.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: